培哚普利联合富马酸比索洛尔对心衰患者心功能、日常生活能力和生活质量的影响

Influence of perindopril combined bisoprolol fumarate on cardiac function,daily living capacity and quality of life in patients with heart failure

目的:探讨培哚普利联合富马酸比索洛尔对心衰患者心功能、日常生活能力和生活质量的影响。方法:2017年8月-2019年2月我院的心衰患者92例被随机均分为比索洛尔组(在常规治疗基础上接受比索洛尔)和联合治疗组(在比索洛尔组基础上接受培哚普利),两组均治疗3个月。观察比较两组治疗前后心功能、Barthel指数、36项简易健康调查表(SF-36)评分、不良反应发生率及治疗总有效率。结果:与比索洛尔组比较,治疗3个月后联合治疗组心肌耗氧量[(137.37±5.66)ml/min比(120.02±12.65)ml/min]显著降低,心输出量[(3.49±0.45)L/min比(4.52±0.73)L/min]、LVEF[(39.58±3.26)%比(45.86±8.64)%]、Barthel指数[(66.95±5.67)分比(69.84±5.82)分]和SF-36得分[(57.47±7.20)分比(67.35±2.14)分]均显著升高,P<0.05或<0.01;不良反应发生率(17.39%比4.34%)显著降低,P=0.044,总有效率(80.43%比97.83%)显著升高,P=0.007。结论:培哚普利联合富马酸比索洛尔对心衰患者疗效显著,可显著改善患者心功能、日常生活能力和生活质量。

Objective:To explore influence of perindopril combined bisoprolol fumarate on cardiac function,daily living capacity and quality of life in patients with heart failure(HF).Methods:A total of 92 HF patients,who were treated in our hospital from Aug 2017 to Feb 2019,were randomly and equally divided into bisoprolol group(received bisoprolol based on routine treatment)and combined treatment group(received perindopril based on bisoprolol group),both groups were treated for three months.Cardiac function,Barthel index,36-item short form health survey(SF-36)score,incidence rate of adverse reactions and total effective rate were observed and compared between two groups before and after treatment.Results:Compared with bisoprolol group after three-month treatment,there was significant reduction in myocardial oxygen consumption[(137.37±5.66)ml/min vs.(120.02±12.65)ml/min],and significant rise in cardiac output[(3.49±0.45)L/min vs.(4.52±0.73)L/min],LVEF[(39.58±3.26)%vs.(45.86±8.64)%],Barthel index[(66.95±5.67)scores vs.(69.84±5.82)scores]and SF-36 score[(57.47±7.20)scores vs.(67.35±2.14)scores],P<0.05 or<0.01;significant reduction in incidence rate of adverse reactions(17.39%vs.4.34%),P=0.044,and significant rise in total effective rate(80.43%vs.97.83%,P=0.007)in combined treatment group.Conclusion:Perindopril combined bisoprolol fumarate possesses significant therapeutic effect on HF patients.It can significantly improve cardiac function,daily living capacity and quality of life in these patients.